ForeSENTIA: Pan-Cancer Plus
The ForeSENTIA Pan-Cancer Plus panel analyses single nucleotide variants, insertions, deletions, copy number alterations, and rearrangements in 222 genes associated with different types of cancers. It can help identify mutations that can be responsible for cancer development and therapy resistance in solid tumours. Depending on the type of cancer and the genetic alterations identified, different FDA/EMA-approved drugs as well as eligible clinical trials are available.
Microsatellite instability (MSI) immunotherapy biomarker is also tested in this panel. FDA/EMA-approved immunotherapies are also available such as pembrolizumab for patients with MSI-high status depending on their type of cancer.
This panel also tests for Tumour Mutational Burden (TMB). TMB score can have a prognostic value for patients with any type of solid tumour. Studies have suggested that patients with TMB-H tumours should be considered for immunotherapy regardless of the tumours’ origin. For example, it was previously shown that TMB-H in ovarian cancer and cutaneous melanoma patients has an important role in prognosis. TMB-H status was also found to be associated with improved survival in different types of cancer – including NSCLC, head and neck cancer, melanoma, colorectal and other cancers – when treated with immunotherapy inhibitors. TMB is considered a new emerging tumour-agnostic biomarker. The FDA-approved immunotherapy drug pembrolizumab can be used to treat all solid tumours with TMB-H, regardless of origin.
Created by
Our editorial team consists of medical specialists and scientists in the field of human genetics. All content is created and reviewed in accordance with current scientific standards.
Are you a patient?
Certified laboratories
